Stock listing

gettex:PHPN Galectin Therapeutics Inc. Aktie

German listing (gettex) of Galectin Therapeutics Inc. · home listing NASDAQ:GALT

Follow Galectin Therapeutics Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:GALT

$2.69 USD -0.29 (-9.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GALT

Past year -53.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.67 – $2.93 USDNov 20, 2026
Volume
257,651 sharesNov 20, 2026
Market cap
$271.4M USDAt the close on Nov 20, 2026 · price × 100.9M shares outstanding
52-week range
$2.03 – $7.13 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$942,183 USDMedian day 227,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Galectin Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GALT · Home$2.69 USD-0.29 (-9.7%)257,651$2.80$2.93$2.67$2.98Close on Nov 20, 2026
Frankfurt:PHPN€2.58 EUR+0.12 (+4.9%)—€2.62€2.62€2.58€2.46Close on Nov 18, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GALT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.69-0.29-9.7%$2.80$2.93$2.67257,651
$2.98+0.07+2.4%$2.94$3.00$2.822233,788
$2.91-0.11-3.6%$3.11$3.20$2.825262,804
$3.02-0.03-1.0%$3.11$3.21$2.93231,993
$3.05-0.09-2.9%$3.16$3.31$2.94181,586
$3.14-0.15-4.6%$3.28$3.534$3.07226,410
$3.29-0.09-2.7%$3.38$3.41$3.2977,977
$3.38-0.08-2.3%$3.44$3.52$3.30167,705
$3.46+0.32+10.2%$3.15$3.49$3.04241,210
$3.14+0.155+5.2%$3.01$3.18$2.90223,428
$2.985-0.485-14.0%$3.50$3.50$2.905396,552
$3.47+0.12+3.6%$3.47$3.59$3.387217,254
$3.35+0.02+0.6%$3.33$3.50$3.33118,233
$3.33+0.01+0.3%$3.35$3.43$3.295117,155
$3.32-0.20-5.7%$3.52$3.54$3.27174,744
$3.52-0.02-0.6%$3.61$3.70$3.448263,857
$3.54+0.16+4.7%$3.37$3.56$3.27141,090
$3.38+0.19+6.0%$3.21$3.44$3.13204,733
$3.190.000.0%$3.20$3.255$3.11164,390
$3.19-0.19-5.6%$3.37$3.37$3.16195,180
$3.38+0.01+0.3%$3.34$3.50$3.27161,500
$3.37-0.06-1.7%$3.46$3.51$3.19295,700
$3.43-0.07-2.0%$3.51$3.62$3.41200,200
$3.50-0.12-3.3%$3.60$3.73$3.47177,300
$3.62-0.09-2.4%$3.71$3.81$3.61169,400
$3.71+0.07+1.9%$3.68$3.84$3.66119,200
$3.64-0.05-1.4%$3.66$3.86$3.61409,000
$3.69-0.18-4.7%$3.84$3.86$3.67184,400
$3.87-0.07-1.8%$3.92$4.01$3.8499,700
$3.94+0.30+8.2%$3.64$3.97$3.64156,400
$3.64+0.02+0.6%$3.62$3.69$3.51270,800
$3.62-0.14-3.7%$3.74$3.86$3.59176,000
$3.76+0.03+0.8%$3.75$3.79$3.57277,900
$3.73-0.17-4.4%$3.84$3.90$3.64280,700
$3.90+0.14+3.7%$3.82$3.94$3.75220,100
$3.76-0.12-3.1%$3.87$4.06$3.68327,400
$3.88-0.03-0.8%$3.90$4.05$3.82198,100
$3.91-0.02-0.5%$3.94$4.00$3.90174,200
$3.93+0.03+0.8%$3.86$3.99$3.80168,800
$3.90-0.06-1.5%$3.93$3.99$3.86124,600
$3.96-0.09-2.2%$4.00$4.04$3.78153,300
$4.05-0.09-2.2%$4.12$4.15$4.00174,000
$4.14+0.18+4.5%$4.05$4.24$4.05258,000
$3.96+0.07+1.8%$3.91$4.02$3.85258,400
$3.89+0.18+4.9%$3.71$3.92$3.681,065,800
$3.71+0.03+0.8%$3.73$3.79$3.69171,100
$3.68-0.05-1.3%$3.71$3.80$3.61274,000
$3.73-0.11-2.9%$3.82$3.83$3.58323,100
$3.84-0.07-1.8%$3.95$4.09$3.82337,900
$3.91+0.01+0.3%$3.92$4.01$3.84243,600
$3.90-0.15-3.7%$4.00$4.05$3.84253,000
$4.05-0.09-2.2%$4.13$4.34$4.04515,600
$4.14-0.47-10.2%$4.60$4.65$4.10393,300
$4.61+0.26+6.0%$4.33$4.72$4.33473,300
$4.35-0.13-2.9%$4.50$4.60$4.22244,100
$4.48+0.31+7.4%$4.19$4.53$4.19460,400
$4.17+0.22+5.6%$3.91$4.39$3.91479,500
$3.95-0.07-1.7%$4.02$4.05$3.91229,700
$4.02-0.12-2.9%$4.14$4.20$3.95271,100
$4.14-0.01-0.2%$4.15$4.45$4.04345,200
$4.15+0.16+4.0%$3.95$4.21$3.92291,100
$3.99+0.11+2.8%$4.07$4.19$3.85194,700
$3.88+0.20+5.4%$3.68$3.97$3.58227,600
$3.68+0.11+3.1%$3.62$3.74$3.59174,900
$3.57-0.10-2.7%$3.67$3.75$3.44313,000

Splits

1 split · NASDAQ:GALT · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
Ticker
gettex:PHPN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Galectin Therapeutics Inc. news

Galectin Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 116 in all · newest Nov 16, 2026 · oldest 2019
Decks
59 decks · latest July 2026

Where Galectin Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GALT · Home listingNASDAQUnited StatesUSD
gettex:PHPN · This pagegettexGermanyEUR
LS Exchange:A1JV3RLS ExchangeGermanyEUR
Lang & Schwarz:A1JV3RLang & SchwarzGermanyEUR
BOATS:GALTBOATSUnited StatesUSD
Dusseldorf:PHPNDusseldorfGermanyEUR
Frankfurt:PHPNFrankfurtGermanyEUR
Munich:PHPNMunichGermanyEUR
Stuttgart:PHPNStuttgartGermanyEUR
Tradegate:PHPNTradegateGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$293.0M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.20

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
AP Biosciences, Inc. · TPEX:6945US$282.2MUS$215.6Mn/an/an/a4.0×n/a0.0×n/a
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.1MUS$225.9Mn/an/an/a5.3×n/a0.0×n/a
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.4MUS$182.7Mn/a467×n/a3.3×n/a0.0×n/a
Agenus Inc. · NASDAQ:AGENUS$270.1MUS$218.3M9.2×1.6×4.0×n/a22.0%n/a1.80
AgomAb Therapeutics NV · NASDAQ:AGMBUS$268.4M−US$6.88Mn/an/an/a0.9×n/a0.0×1.29
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Median of the othersUS$273.8MUS$145.2M9.2×234×4.0×2.0×22.0%0.0×1.46

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
11.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.26 · 1 analyst

Team and board

Officers

OfficerRole
Joel LewisChief Executive Officer (CEO) and President
Jack W. CallicuttChief Financial Officer
Andrew VolosovVice President, Clinical Pharmacology and Pharmacokinetics
Sharisse BruttoVice President, Project Management
Jim WilkinsHead of CMC and Pharmaceutical Development
Khurram JamilChief Medical Officer

Board

DirectorRole
Richard E. UihleinChairman of the Board
Benjamin S. CarsonIndependent Director
Elissa J. SchwartzIndependent Director
Gilbert F. AmelioIndependent Director
Gilbert S. OmennIndependent Director
Henry BremIndependent Director
Kary EldredIndependent Director
Kevin D. FreemanVice Chairman of the Board
Richard A. ZordaniIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−1.0%
Q2 2026Aug 14, 2026 · Before open−2.5%
Q1 2026May 15, 2026 · Before open−7.7%
Q4 2025Mar 26, 2026−8.5%
Q3 2025Nov 14, 2025 · Before open−0.4%
Q2 2025Aug 14, 2025 · Before open+2.5%
Q1 2025May 15, 2025 · Before open+1.5%
Q4 2024Mar 27, 2025 · Before open+2.4%
Q3 2024Nov 14, 2024 · Before open−5.2%
Q2 2024Aug 13, 2024 · Before open+6.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open+7.8%
Q4 2023Mar 29, 2024 · Before open+2.1%
Q3 2023Nov 13, 2023 · Before open−7.1%
Q2 2023Aug 14, 2023 · Before open0.0%
Q1 2023May 15, 2023 · Before open−3.0%
Q4 2022Mar 30, 2023 · Before open+5.3%
Q3 2022Nov 14, 2022 · Before open+5.6%
Q2 2022Aug 15, 2022 · Before open+5.3%
Q1 2022May 16, 2022 · Before open−7.3%
Q4 2021Mar 31, 2022 · Before open−5.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck51 slidesJuly 2026
Technical Presentation (March 2026)Technical33 slidesMar 10, 2026
Investor Presentation (November 2025)Investor deck54 slidesNov 10, 2025
Investor Presentation (September 2025)Investor deck40 slidesSep 8, 2025
Technical Presentation (June 2025)Technical26 slidesJun 16, 2025
Investor Presentation (May 2025)Investor deck38 slidesMay 12, 2025
Investor Presentation (March 2025)Investor deck33 slidesMar 5, 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck24 slidesNov 14, 2024
Investor Presentation (September 2024)Investor deck23 slidesSep 9, 2024
Show 50 decks
DeckKindSlidesDate
Investor Presentation (January 2024)Investor deck21 slidesJanuary 2024
Investor Presentation (August 2023)Investor deck20 slidesAugust 2023
Investor Presentation (September 2021)Investor deck25 slidesSep 13, 2021
Investor Presentation (March 2021)Investor deck23 slidesMar 9, 2021
Investor Presentation (September 2020)Investor deck23 slidesSep 29, 2020
Shareholder Meeting (December 2019)Shareholder meeting27 slidesDec 4, 2019
Shareholder Meeting (December 2019)Shareholder meeting27 slidesDec 4, 2019
Technical Presentation (November 2019)Technical33 slidesNov 18, 2019
Investor Presentation (March 2019)Investor deck44 slidesMarch 2019
Anti-Fibrotic Drug Development Summit 2018Conference45 slidesNov 29, 2018
Investor Presentation (July 2018)Investor deck40 slidesJuly 2018
NASH Summit 2018Conference30 slidesApr 25, 2018
Technical Presentation (April 2018)Technical19 slidesApr 16, 2018
Technical Presentation (April 2018)Technical19 slidesApr 12, 2018
Investor Presentation (February 2018)Investor deck21 slidesFeb 6, 2018
Investor Presentation (February 2018)Investor deck22 slidesFeb 6, 2018
Investor Presentation (February 2018)Investor deck26 slidesFeb 6, 2018
Conference Presentation (January 2018)Conference25 slidesJan 4, 2018
Technical Presentation (December 2017)Technical25 slidesDec 5, 2017
Investor Presentation (February 2017)Investor deck29 slidesFeb 2, 2017
Investor Presentation (August 2016)Investor deck26 slidesAugust 2016
Investor Presentation (February 2016)Investor deck35 slidesFeb 8, 2016
Investor Presentation (January 2016)Investor deck32 slidesJan 8, 2016
Rodman & Renshaw 17th Annual Global Investment Conference (September 2015)Conference25 slidesSep 10, 2015
Shareholder Meeting (May 2015)Shareholder meeting32 slidesMay 21, 2015
Investor Presentation (May 2015)Investor deck32 slidesMay 11, 2015
Investor Presentation (February 2015)Investor deck38 slidesFeb 24, 2015
Investor Presentation (January 2015)Investor deck38 slidesJan 7, 2015
Investor Presentation (January 2015)Investor deck38 slidesJan 7, 2015
Technical Presentation (November 2014)Technical17 slidesNov 10, 2014
Investor Presentation (September 2014)Investor deck27 slidesSep 12, 2014
Technical Presentation (July 2014)Technical24 slidesJul 29, 2014
Shareholder Meeting (May 2014)Shareholder meeting30 slidesMay 14, 2014
Technical Presentation (March 2014)Technical31 slidesMar 31, 2014
Investor Presentation (February 2014)Investor deck33 slidesFeb 10, 2014
Investor Presentation (February 2014)Investor deck33 slidesFeb 10, 2014
Investor Presentation (January 2014)Investor deck35 slidesJan 13, 2014
Investor Presentation (September 2013)Investor deck38 slidesSep 24, 2013
Investor Presentation (March 2013)Investor deck35 slidesMar 11, 2013
Investor Presentation (February 2013)Investor deck33 slidesFeb 5, 2013

This page holds 50 of 59 decks. Open Decks

Open Decks

Financings

RaiseDate
Unsecured, convertible line of credit
Announced: convertible
Buyers: Richard E. Uihlein (Chairman; provides a new $10 million unsecured, convertible line of credit)
Insiders: Line of credit provided by the company's chairman, Richard E. Uihlein
Use of proceeds: Together with cash, to fund currently expected expenditures through at least March 2027
Dec 19, 2025
Convertible promissory notes under an unsecured line of credit, with stock purchase warrants
Announced: up to 200,000 stock purchase warrants (20,000 per $1 million of borrowings), exercise…
Buyers: Richard E. Uihlein (Provides the new $10 million unsecured convertible line of credit)
Insiders: The credit line is provided by Richard E. Uihlein, Chairman of the Board and largest individual stockholder
Use of proceeds: To cover projected expenditures through June 2026
Jul 9, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue37.0K33.0K32.0K41.0K36.0K35.0K1.00K1.00K7.00K
Gross profit-37.0K-33.0K-32.0K-41.0K-36.0K-35.0K-1.00K-1.00K-7.00K
Research and development14.3M36.6M32.1M31.7M23.8M18.0M7.47M6.47M11.7M15.3M
Selling, general and administrative5.79M5.86M5.94M6.62M6.36M5.47M5.97M7.13M4.53M6.16M
Operating income-20.1M-42.4M-38.1M-38.4M-30.2M-23.4M-13.4M-13.6M-16.2M-21.5M
Depreciation and amortization53.0K00000001.00K7.00K
EBITDA-20.0M-42.4M-38.1M-38.4M-30.2M-23.4M-13.4M-13.6M-16.2M-21.5M
Interest expense7.33M5.54M2.79M1.03M489.0K87.0K87.0K336.0K12.0K0
Income before tax-30.8M-47.0M-41.1M-38.8M-30.5M-23.5M-13.3M-13.9M-16.2M-21.4M
Income tax00-2.99M424.0K448.0K51.0K87.0K024.0K0
Net income-30.8M-47.0M-41.1M-38.8M-30.5M-23.5M-13.3M-13.9M-16.2M-21.4M
Earnings per share, basic-0.48-0.76-0.74-0.65-0.52-0.41-0.39-0.38-0.49-0.76
Earnings per share, diluted-0.48-0.76-0.74-0.65-0.52-0.41-0.39-0.38-0.49-0.76

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents17.7M15.1M25.7M18.6M39.6M27.1M47.5M8.25M3.05M15.4M
Short-term investments00
Inventory00
Current assets19.4M17.3M27.7M20.6M41.8M29.5M48.2M8.83M3.82M15.8M
Property, plant and equipment0000000000
Goodwill01.00K
Total assets19.5M17.5M28.2M21.3M41.8M29.6M48.5M9.01M4.16M15.8M
Accounts payable3.25M5.66M6.43M3.89M1.80M1.29M1.66M297.0K608.0K910.0K
Current liabilities8.03M35.4M15.7M13.0M9.03M5.40M2.82M2.11M2.97M3.78M
Long-term debt133.7M85.1M71.7M39.8M29.0M00
Total debt133.8M106.2M71.8M39.9M29.1M44.0K39.0K
Total liabilities145.7M120.6M88.4M53.5M39.2M5.41M2.87M2.11M2.97M3.78M
Shareholders' equity-127.9M-104.8M-62.0M-33.9M893.0K22.5M43.9M5.17M-530.0K10.3M
Shares outstanding65.2M63.2M61.9M59.4M59.3M57.1M56.9M41.2M35.8M32.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-23.9M-41.8M-33.0M-31.1M-24.3M-20.6M-10.8M-10.2M-15.9M-16.4M
Capital spending0000000000
Free cash flow-23.9M-41.8M-33.0M-31.1M-24.3M-20.6M-10.8M-10.2M-15.9M-16.4M
Cash from investing000000000
Cash from financing26.5M31.2M40.0M10.0M36.8M263.0K50.1M15.4M3.58M5.92M
Dividends paid-138.0K-91.0K-120.0K-97.0K-171.0K-137.0K-394.0K-915.0K-1.23M-741.0K
Share buybacks667.0K845.0K671.0K899.0K-30.0M263.0K50.5M15.4M696.0K5.92M
Change in cash2.60M-10.5M7.07M-21.1M12.5M-20.3M39.2M5.20M-12.3M-10.5M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026ResultsSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
ARS · Annual report to shareholdersOct 13, 2026Annual reportSEC
DEFA14A · Additional proxy materialOct 13, 2026Meeting noticeSEC
DEF 14A · Proxy statementOct 13, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 2, 2026Meeting noticeSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 4, 2026Big-stake noticeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 4, 2026FinancingSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
8-K · Current reportJun 23, 2026Current reportSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 15, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 13, 2026Other filingsSEC
CORRESP · Letter to the SECApr 8, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 6, 2026Other filingsSEC
S-3 · Registration statementMar 31, 2026Offer documentSEC
8-K · Current reportMar 31, 2026ResultsSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 17, 2026Insider tradeSEC
8-K · Current reportMar 17, 2026Management or board changeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 21, 2026Management or board changeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Management or board changeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedJan 5, 2026Other filingsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleDec 31, 2025Other filingsSEC
4/A · Change in ownership, amendedDec 23, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
8-K · Current reportDec 19, 2025Material contractSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
4/A · Change in ownership, amendedDec 8, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Meeting outcomeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
8-K · Current reportDec 3, 2025Current reportSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
8-K · Current reportNov 10, 2025Current reportSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
ARS · Annual report to shareholdersOct 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialOct 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 22, 2025Meeting noticeSEC
5 · Annual statement of ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
8-K · Current reportSep 8, 2025Current reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
8-K · Current reportJul 9, 2025Material contractSEC
8-K · Current reportJun 16, 2025Current reportSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
5 · Annual statement of ownershipJun 11, 2025Insider tradeSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025Current reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 5, 2025Current reportSEC
8-K · Current reportFeb 18, 2025Current reportSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
8-K · Current reportJan 28, 2025Meeting outcomeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
8-K · Current reportJan 23, 2025Current reportSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
144 · Notice of proposed saleDec 23, 2024Other filingsSEC
144 · Notice of proposed saleDec 23, 2024Other filingsSEC
144 · Notice of proposed saleDec 23, 2024Other filingsSEC
8-K · Current reportDec 20, 2024Current reportSEC
ARS · Annual report to shareholdersDec 3, 2024Annual reportSEC
DEFA14A · Additional proxy materialDec 3, 2024Meeting noticeSEC
DEF 14A · Proxy statementDec 3, 2024Meeting noticeSEC
8-K · Current reportNov 14, 2024Current reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
144 · Notice of proposed saleOct 4, 2024Other filingsSEC
8-K · Current reportSep 9, 2024Current reportSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2024Insider tradeSEC
8-K · Current reportAug 1, 2024Management or board changeSEC
4/A · Change in ownership, amendedJul 23, 2024Insider tradeSEC
4 · Change in ownershipJul 23, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
4 · Change in ownershipApr 30, 2024Insider tradeSEC
4 · Change in ownershipApr 25, 2024Insider tradeSEC
5 · Annual statement of ownershipApr 25, 2024Insider tradeSEC
4 · Change in ownershipApr 25, 2024Insider tradeSEC
4 · Change in ownershipApr 22, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
8-K · Current reportMar 29, 2024ResultsSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipFeb 7, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
8-K · Current reportDec 11, 2023Meeting outcomeSEC
8-K · Current reportDec 7, 2023Current reportSEC
5 · Annual statement of ownershipDec 1, 2023Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Galectin Therapeutics Inc.’s releases · as of Nov 6, 2026

Common shares
100,875,106
Fully diluted
100,875,106

Fully diluted

LineSharesAs of
Common shares100,875,106Nov 6, 2026

Share count over time

CountShares
Nov 6, 2026100,875,106

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock3.38M3.3%US$13.1MSep 30, 2026
Vanguard2.78M2.8%US$10.8MSep 30, 2026
Geode Capital1.25M1.2%US$4.84MSep 30, 2026
Osaic Holdings, Inc.1.21M1.2%US$4.7MSep 30, 2026
State Street801K0.79%US$3.11MSep 30, 2026
Wealthspire Advisors, LLC722K0.72%US$2.8MSep 30, 2026
Corient Private Wealth LP542K0.54%US$2.1MSep 30, 2026
Marshall Wace, LLP467K0.46%US$1.81MSep 30, 2026
Commonwealth Equity Services, LLC460K0.46%US$1.79MSep 30, 2026
Northern Trust376K0.37%US$1.46MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
LPL Financial LLC285K0.28%US$1.11MSep 30, 2026
Sovran Advisors, LLC252K0.25%US$885KSep 30, 2026
Geneos Wealth Management Inc.238K0.24%US$922KSep 30, 2026
Retirement Guys Formula LLC221K0.22%US$856KSep 30, 2026
UBS213K0.21%US$828KSep 30, 2026
Citadel191K0.19%US$739KSep 30, 2026
Schwab172K0.17%US$667KSep 30, 2026
Blair William & Co149K0.15%US$579KSep 30, 2026
Gsa Capital Partners LLP147K0.15%US$569KSep 30, 2026
Goldman Sachs139K0.14%US$538KSep 30, 2026
Cambridge Investment Research Advisors, Inc.130K0.13%US$506KSep 30, 2026
Morgan Stanley128K0.13%US$495KSep 30, 2026
National Bank Of Canada119K0.12%US$463KSep 30, 2026
Renaissance Technologies111K0.11%US$429KSep 30, 2026
BNY108K0.11%US$420KSep 30, 2026
Two Sigma102K0.10%US$395KSep 30, 2026
HighTower Advisors, LLC94,7600.09%US$368KSep 30, 2026
Creative Planning87,4990.09%US$339KSep 30, 2026
Nuveen71,7210.07%US$278KSep 30, 2026
Hopwood Nicholas Hunter69,2700.07%US$269KSep 30, 2026
Truist Financial Corp68,0000.07%US$264KSep 30, 2026
Bank of America65,0870.06%US$253KSep 30, 2026
Rhumbline Advisers52,5050.05%US$204KSep 30, 2026
Horizon Kinetics Asset Management LLC42,4520.04%US$165KSep 30, 2026
DWS42,3890.04%US$164KSep 30, 2026
Pinnacle Financial Partners, Inc.41,6500.04%US$162KSep 30, 2026
T. Rowe Price39,3130.04%US$153KSep 30, 2026
Sanctuary Advisors, LLC36,9830.04%US$143KSep 30, 2026
JPMorgan35,7410.04%US$140KSep 30, 2026
Pekin Hardy Strauss, Inc.30,0000.03%US$116KSep 30, 2026
Squarepoint Ops LLC28,1930.03%US$109KSep 30, 2026
Invesco26,2830.03%US$102KSep 30, 2026
Solutions 4 Wealth, Ltd25,0270.02%US$97,105Sep 30, 2026
Gladstone Institutional Advisory LLC23,9000.02%US$92,732Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.23,2480.02%US$90,202Sep 30, 2026
Cahaba Wealth Management, Inc.21,0000.02%US$81,480Sep 30, 2026
Mariner, LLC19,3600.02%US$75,118Sep 30, 2026
Stratos Wealth Partners, LTD.19,0880.02%US$74,061Sep 30, 2026
Barclays18,7730.02%US$72,839Sep 30, 2026
Wells Fargo18,3370.02%US$71,148Sep 30, 2026

This page holds 50 of 102 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.52M1.5%US$7.06MJun 30, 2026
iShares Russell 2000 ETF951K0.94%US$4.41MJun 30, 2026
Vanguard Extended Market Index Fund595K0.59%US$2.76MJun 30, 2026
Fidelity Small Cap Index Fund520K0.52%US$1.55MJul 31, 2026
iShares Russell 2000 Growth ETF310K0.31%US$1.44MJun 30, 2026
Fidelity Extended Market Index Fund272K0.27%US$684KMay 31, 2026
iShares Micro-Cap ETF161K0.16%US$745KJun 30, 2026
Schwab Small-Cap Index Fund116K0.12%US$346KJul 31, 2026
iShares Russell 2000 Value ETF113K0.11%US$524KJun 30, 2026
Fidelity Total Market Index Fund95,4890.09%US$241KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Master Small Cap Index Series89,5770.09%US$416KJun 30, 2026
Fidelity Series Total Market Index Fund78,3020.08%US$197KMay 31, 2026
Nuveen Small Cap Blend Index Fund63,7100.06%US$189KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund48,0310.05%US$223KJun 30, 2026
EQ/2000 Managed Volatility Portfolio47,6860.05%US$221KJun 30, 2026
Horizon Kinetics Medical ETF46,9680.05%US$218KJun 30, 2026
Fidelity Nasdaq Composite Index Fund45,6150.05%US$115KMay 31, 2026
LVIP State Street Small-Cap Index Fund35,8000.04%US$166KJun 30, 2026
Fidelity Small Cap Growth Index Fund30,8070.03%US$143KJun 30, 2026
Vanguard Balanced Index Fund26,9020.03%US$125KJun 30, 2026
Fidelity ZERO Total Market Index Fund26,7050.03%US$79,314Jul 31, 2026
Invesco NASDAQ Future Gen 200 ETF25,7860.03%US$64,981May 31, 2026
Small Cap Index Fund24,9710.02%US$116KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund24,5670.02%US$114KJun 30, 2026
Global X Russell 2000 ETF22,8880.02%US$67,977Jul 31, 2026
Fidelity Small Cap Value Index Fund20,3430.02%US$94,392Jun 30, 2026
Fidelity ZERO Extended Market Index Fund19,9050.02%US$59,118Jul 31, 2026
MetLife Russell 2000 Index Portfolio16,3770.02%US$75,989Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio16,0000.02%US$74,240Jun 30, 2026
Small-Cap Index Portfolio12,6130.01%US$58,524Jun 30, 2026
1290 VT Micro Cap Portfolio10,7840.01%US$50,038Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio10,1580.01%US$47,133Jun 30, 2026
NVIT Small Cap Index Fund9,960<0.01%US$46,214Jun 30, 2026
Fidelity Flex Small Cap Index Fund8,649<0.01%US$25,688Jul 31, 2026
DWS Small Cap Index VIP7,501<0.01%US$34,805Jun 30, 2026
T. Rowe Price Small-Cap Index Fund7,224<0.01%US$33,519Jun 30, 2026
BlackRock Small Cap Index V.I. Fund6,110<0.01%US$28,350Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio6,042<0.01%US$28,035Jun 30, 2026
SA Small Cap Index Portfolio5,612<0.01%US$16,668Jul 31, 2026
EQ/Small Company Index Portfolio5,600<0.01%US$25,984Jun 30, 2026
EQ/AB Small Cap Growth Portfolio5,600<0.01%US$25,984Jun 30, 2026
Victory Extended Market Index Fund5,424<0.01%US$16,109Jul 31, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio4,864<0.01%US$22,569Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund4,684<0.01%US$13,911Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio4,349<0.01%US$20,179Jun 30, 2026
Nationwide Small Cap Index Fund4,010<0.01%US$11,910Jul 31, 2026
Venerable Small Cap Index Fund3,832<0.01%US$17,780Jun 30, 2026
VIP Extended Market Index Portfolio3,743<0.01%US$17,368Jun 30, 2026
Voya VACS Index Series SC Portfolio3,643<0.01%US$16,904Jun 30, 2026
Nationwide Fundamental All Cap Equity Portfolio3,637<0.01%US$10,802Jul 31, 2026

This page holds 50 of 68 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Jamil Khurram
Officer: Chief Medical Officer
Sale16,250USD 5.13US$83,363Jul 14, 2026
Jamil Khurram
Officer: Chief Medical Officer
Sale47,467USD 5.04US$239KJun 29, 2026
Shlevin Harold H.
Director
Sale22,268USD 5.04US$112KJun 29, 2026
Jamil Khurram
Officer: Chief Medical Officer
Sale2,037USD 5.00US$10,185Jun 26, 2026
Jamil Khurram
Officer: Chief Medical Officer
Sale2,533USD 5.00US$12,665Jun 26, 2026
Shlevin Harold H.
Director
Sale7,732USD 5.00US$38,660Jun 26, 2026
Jamil Khurram
Officer: Chief Medical Officer
Sale7,557USD 3.14US$23,729Jun 23, 2026
Jamil Khurram
Officer: Chief Medical Officer
Sale568USD 3.10US$1,761May 26, 2026

Big stakes

StakeStakeSharesDateFiling
Richard E. Uihlein49.30%54.7MJul 31, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Benjamin Carson Sr
Other companies: Sinclair, Inc. (Director · Since at least Jun 11, 2024); Covenant Logistics Group, Inc. (Director · Since at least Jul 7, 2021); D.R. Horton, Inc. (Director · Since at least Apr 20, 2021); Vaccinogen Inc (Director · Aug 22, 2014 – Apr 20, 2015 · Past); Costco Wholesale Corporation (Director · Apr 27, 2006 – Feb 27, 2015 · Past)
Director · Since at least Dec 7, 2023
Gilbert F. Amelio
Other companies: 5BARz International Inc (Director · Nov 21, 2013 – Jul 8, 2014 · Past); InterDigital, Inc. (Director · Mar 1, 2011 – Apr 29, 2015 · Past); Jazz Technologies Inc (Chairman and CEO, Director · May 16, 2007 – Dec 17, 2007 · Past); AT&T Inc. (Director · Jan 31, 2006 – Apr 30, 2013 · Past)
Independent Director · Since at least Feb 12, 2009
Sydney Colin Neill
Other companies: Boston Therapeutics Inc (Director · Dec 3, 2013 – Feb 12, 2014 · Past); Pharmos Corp (President and CFO · Oct 5, 2006 – Jan 23, 2008 · Past); Raptor Pharmaceutical Corp (Chief Financial Officer · Aug 23, 2006 – Aug 23, 2006 · Past); GT Biopharma, Inc. (Director · Aug 1, 2006 – Nov 9, 2007 · Past)
Director · May 24, 2007 – Jun 28, 2011 · Past
Marc Rubin
Other companies: Curis, Inc. (Director · Since at least Jun 3, 2010); Medicine Man Technologies Inc. (Director · Oct 28, 2022 – Oct 28, 2022 · Past); Titan Pharmaceuticals Inc (Executive Chairman, Director · Oct 1, 2007 – Jan 5, 2022 · Past)
Director · Oct 12, 2011 – Jan 23, 2025 · Past
Peter Traber
Other companies: Cartesian Therapeutics, Inc. (Head of Research and Development · Since at least Aug 1, 2020); Lisata Therapeutics, Inc. (Director · Jan 22, 2015 – Jan 10, 2022 · Past); Tanox Inc (Director · Jun 2, 2006 – Jun 2, 2006 · Past)
President & CEO · Feb 12, 2009 – Jun 13, 2018 · Past
Dale H. Conaway
Other companies: Bioxytran, Inc. (Director · Since at least Jul 1, 2020); Boston Therapeutics Inc (Director · Apr 4, 2014 – May 15, 2015 · Past)
Director · Mar 9, 2006 – Feb 8, 2009 · Past
Gilbert S. Omenn
Other companies: Amesite Inc. (Director · Since at least Sep 25, 2020); Elicio Therapeutics, Inc. (Director · Feb 4, 2021 – Jun 9, 2022 · Past)
Director · Since at least Dec 14, 2017
Pol F. Boudes
Other companies: Protalix BioTherapeutics, Inc. (de) (Director · Since at least Jan 1, 2020); Amicus Therapeutics Inc (Chief Medical Officer · Jun 15, 2010 – Jun 4, 2012 · Past)
Chief Medical Officer · Mar 2, 2020 – Jan 24, 2024 · Past
Steven Prelack
Other companies: Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 30, 2021 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2019 · Past)
Director · Mar 9, 2006 – Dec 15, 2016 · Past
Anthony Don Squeglia
Other companies: Boston Therapeutics Inc (Chief Financial Officer · Dec 3, 2013 – Mar 10, 2015 · Past)
Chief Financial Officer · Oct 1, 2007 – Feb 2, 2010 · Past
All 37 people
PersonSeat
Carl Laurence Lueders
Other companies: Micronetics Inc (Chief Financial Officer · Aug 18, 2008 – Aug 8, 2012 · Past)
Chief Financial Officer · Mar 9, 2006 – Mar 8, 2007 · Past
Henry Brem
Other companies: Alseres Pharmaceuticals Inc (Director · Dec 6, 2007 – Jan 14, 2009 · Past)
Independent Director · Since at least Mar 12, 2026
Jack W Callicutt
Other companies: Vystar Corporation (Chief Financial Officer · Apr 12, 2010 – Mar 14, 2011 · Past)
Chief Financial Officer · Since at least Jul 1, 2013
James C Czirr
Other companies: Mitesco, Inc. (Director · Feb 7, 2017 – Feb 7, 2017 · Past)
Director · Jan 21, 2009 – Dec 1, 2023 · Past
Andrew VolosovVice President, Clinical Pharmacology and Pharmacokinetics · Since at least Nov 4, 2026
Arthur GreenbergDirector · Aug 24, 2009 – Dec 15, 2016 · Past
Benjamin S. CarsonIndependent Director · Since at least Nov 5, 2026
Elissa J. SchwartzIndependent Director · Since at least Aug 31, 2020
Harold ShlevinDirector · Since at least Jan 26, 2023
Herman Paul PresslerDirector · May 26, 2011 – Mar 12, 2015 · Past
Jack W. CallicuttChief Financial Officer · Since at least Oct 6, 2026
James Theophile GourzisDirector · Feb 8, 2009 – Feb 8, 2009 · Past
Jerald K RomeDirector · Mar 7, 2013 – Mar 28, 2013 · Past
Jim WilkinsHead of CMC and Pharmaceutical Development · Since at least Nov 4, 2026
Joel LewisChief Executive Officer (CEO) and President · Since at least Dec 14, 2017
Kary EldredDirector · Since at least May 22, 2018
Kevin D. FreemanVice Chairman of the Board · Since at least May 26, 2011
Khurram JamilChief Medical Officer · Since at least Aug 1, 2024
Maureen FoleyChief Operating Officer · Mar 9, 2006 – Feb 2, 2010 · Past
Mildred S ChristianDirector · Mar 9, 2006 – Feb 25, 2009 · Past
Richard A. ZordaniIndependent Director · Since at least Nov 5, 2026
Richard A Zordani JrDirector · Since at least Jan 24, 2024
Richard E. UihleinDirector · Since at least Jan 24, 2024
Rod D MartinDirector · Feb 12, 2009 – Mar 12, 2015 · Past
Sharisse BruttoVice President, Project Management · Since at least Nov 5, 2026
Stephen ShulmanDirector · Dec 14, 2017 – Jan 16, 2019 · Past
Theodore Daniel ZucconiDirector · Dec 14, 2017 – Apr 16, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Galectin Therapeutics Inc.